Eton Pharmaceuticals, Inc. ETON
Set alert
50.81 USD -1.37 -2.63%
At close · Nov 2
50.81 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
49.49 Day range 53.75
14.27 52-week range 66.37
- YTD
- +200.47%
- 1 year
- +182.12%
- Open
- 52.92
- Prev close
- 52.18
- Mkt cap
- 1.45B
- Vol
- 557.15K
- Avg vol
- 562.95K
- EPS
- 0.40
- P/E
- 127.03
- Div yield
- 0.00%
More statistics
- Low
- 49.49
- High
- 53.75
- Forward P/E
- 19.93
- Beta
- 0.83
- Short ratio
- 3.18
- Inst. own
- 71.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 56.00
- 200-d avg
- 35.71
- 1y target
- 71.50
1M chart
Events in this range
- Oct 14, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (6)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 13 hours ago |
| MACD: Buy Signal | Oct 29, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 1.45B
- Enterprise value
- 1.49B
- Trailing P/E
- 127.03
- Forward P/E
- 19.93
- PEG ratio
- 0.00
- Price / sales
- 13.75
- Price / book
- 30.85
- EPS (TTM)
- 0.40
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.02%
- Revenue (TTM)
- 105.59M
- Revenue growth
- 98.60%
- Free cash flow
- 6.58M
- Total cash
- 26.84M
- Total debt
- 29.23M
- Return on equity
- 35.97%
- Shares outstanding
- 28.58M
- Short % of float
- 9.40%
- 50-day average
- 56.00
- 200-day average
- 35.71
Analyst view
Consensus: none
Price target (mean) 71.50 +40.7% upside
Now 50.81
- Target (low)
- 68.00
- Target (mean)
- 71.50
- Target (high)
- 78.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.37.
Financials — quick view
ETON Revenue — quarterly 37.59M
ETON Net income — quarterly 11.58M
ETON EPS — quarterly 0.42
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.3125 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | 0.1898 | 0.35 | +0.16 | +84.40% |
| May 14, 2026 | Mar 31, 2026 | 0.10 | 0.05 | -0.05 | -50.00% |
| Mar 19, 2026 | Dec 31, 2025 | 0.12 | 0.05 | -0.07 | -58.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.16 | -0.07 | -0.23 | -143.75% |
| Aug 7, 2025 | Jun 30, 2025 | -0.01 | -0.10 | -0.09 | -900.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | B. Riley Securities | reit | Buy | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 28, 2026 | Craig-Hallum | main | Buy | Buy |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- etonpharma.com
News
- ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
- Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027
- Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
- Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.
- Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
- HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target
- Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
- Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
- Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)
Your note
Sign in to keep a note on ETON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JENNIFER MCKIE | Director | Sale | Jun 16, 2026 | 0 |
| BRYNJELSEN SEAN E | Chief Executive Officer | Sale | Aug 19, 2026 | 961,194 |
| GRUBER JAMES R | Chief Financial Officer | Sale | Aug 19, 2025 | 204,753 |
| KREMPA DAVID | Officer | Sale | Oct 5, 2026 | 43,381 |
| MAIER PAUL V | Director | Sale | Aug 27, 2026 | 59,745 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 10.01% | 2,860,000 | 145.32M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 7.60% | 2,171,938 | 110.36M | Jun 29, 2026 |
| Blackrock Inc. | 6.63% | 1,895,833 | 96.33M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 4.11% | 1,175,951 | 59.75M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.42% | 976,570 | 49.62M | Jun 29, 2026 |
| Morgan Stanley | 2.69% | 767,972 | 39.02M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 690,942 | 35.11M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.40% | 684,821 | 34.80M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.69% | 483,900 | 24.59M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 291,898 | 14.83M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 271,079 | 13.77M | Jun 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.89% | 253,380 | 12.87M | Jul 30, 2026 |